World's Best Scientists 2026 revealed!
Award Badge
Biology and Biochemistry
UK
2026

D-Index & Metrics

Biology and Biochemistry

D-Index
123
Citations
58819
World Ranking
551
National Ranking
31

Paul Workman publication distribution in Biology and Biochemistry in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Biology and Biochemistry in 2026. The highlighted bar marks where Paul Workman sits on this spectrum.

47–56 publications: 8 scientists 57–66 publications: 35 scientists 67–76 publications: 106 scientists 77–86 publications: 231 scientists 87–96 publications: 414 scientists 97–106 publications: 546 scientists 107–116 publications: 704 scientists 117–126 publications: 849 scientists 127–136 publications: 980 scientists 137–146 publications: 942 scientists 147–156 publications: 969 scientists 157–166 publications: 950 scientists 167–176 publications: 951 scientists 177–186 publications: 915 scientists 187–196 publications: 787 scientists 197–206 publications: 841 scientists 207–216 publications: 735 scientists 217–226 publications: 709 scientists 227–236 publications: 651 scientists 237–246 publications: 605 scientists 247–256 publications: 510 scientists 257–266 publications: 524 scientists 267–276 publications: 434 scientists 277–286 publications: 418 scientists 287–296 publications: 350 scientists 297–306 publications: 363 scientists 307–316 publications: 315 scientists 317–326 publications: 296 scientists 327–336 publications: 261 scientists 337–346 publications: 240 scientists 347–356 publications: 219 scientists 357–366 publications: 197 scientists 367–376 publications: 154 scientists 377–386 publications: 161 scientists 387–396 publications: 155 scientists 397–406 publications: 145 scientists 407–416 publications: 124 scientists 417–426 publications: 112 scientists 427–436 publications: 132 scientists 437–446 publications: 116 scientists 447–456 publications: 99 scientists 457–466 publications: 81 scientists 467–476 publications: 91 scientists 477–486 publications: 80 scientists 487–496 publications: 80 scientists 497–506 publications: 60 scientists 507–516 publications: 36 scientists 517–526 publications: 46 scientists 527–536 publications: 54 scientists 537–546 publications: 44 scientists 547–556 publications: 43 scientists 557–566 publications: 43 scientists 567–576 publications: 42 scientists 577–586 publications: 25 scientists 587–596 publications: 34 scientists 597–606 publications: 23 scientists 607–616 publications: 33 scientists 617–626 publications: 31 scientists 627–636 publications: 27 scientists 637–646 publications: 25 scientists 647–656 publications: 28 scientists 657–666 publications: 34 scientists 667–676 publications: 18 scientists 677–686 publications: 16 scientists 687–696 publications: 10 scientists 697–706 publications: 12 scientists 707–716 publications: 21 scientists 717–726 publications: 12 scientists 727–736 publications: 12 scientists 737–746 publications: 10 scientists 747–756 publications: 7 scientists 757–766 publications: 13 scientists 767–776 publications: 15 scientists 777–786 publications: 13 scientists 787–796 publications: 9 scientists 797–806 publications: 9 scientists 807–816 publications: 7 scientists 817–826 publications: 4 scientists 827–836 publications: 9 scientists 837–846 publications: 7 scientists 847–856 publications: 3 scientists 857–866 publications: 5 scientists 867–876 publications: 5 scientists 877–886 publications: 11 scientists 887–896 publications: 3 scientists 897–906 publications: 4 scientists 907–916 publications: 7 scientists 917–926 publications: 5 scientists 927–936 publications: 6 scientists 937–946 publications: 6 scientists 947–956 publications: 3 scientists 957–966 publications: 7 scientists 967–976 publications: 2 scientists 977–986 publications: 2 scientists 987–996 publications: 1 scientists 997–1,006 publications: 5 scientists 1,007–1,016 publications: 2 scientists 1,017–1,026 publications: 2 scientists 1,027 publications: 1 scientists 1,028+ publications: 100 scientists
47 publications 1,028+

This scientist: 771 publications — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,028 publications or more.

Paul Workman D-index placement in Biology and Biochemistry in 2026

The chart shows the D-index (discipline H-index) distribution of Biology and Biochemistry scientists ranked by Research.com in 2026. The highlighted bar marks where Paul Workman sits on this spectrum.

40–41 D-Index: 80 scientists 42–43 D-Index: 183 scientists 44–45 D-Index: 317 scientists 46–47 D-Index: 504 scientists 48–49 D-Index: 718 scientists 50–51 D-Index: 900 scientists 52–53 D-Index: 1,026 scientists 54–55 D-Index: 1,150 scientists 56–57 D-Index: 1,236 scientists 58–59 D-Index: 1,253 scientists 60–61 D-Index: 1,163 scientists 62–63 D-Index: 1,131 scientists 64–65 D-Index: 1,032 scientists 66–67 D-Index: 897 scientists 68–69 D-Index: 814 scientists 70–71 D-Index: 715 scientists 72–73 D-Index: 709 scientists 74–75 D-Index: 596 scientists 76–77 D-Index: 512 scientists 78–79 D-Index: 473 scientists 80–81 D-Index: 412 scientists 82–83 D-Index: 373 scientists 84–85 D-Index: 358 scientists 86–87 D-Index: 285 scientists 88–89 D-Index: 273 scientists 90–91 D-Index: 227 scientists 92–93 D-Index: 208 scientists 94–95 D-Index: 193 scientists 96–97 D-Index: 153 scientists 98–99 D-Index: 157 scientists 100–101 D-Index: 148 scientists 102–103 D-Index: 120 scientists 104–105 D-Index: 113 scientists 106–107 D-Index: 100 scientists 108–109 D-Index: 86 scientists 110–111 D-Index: 67 scientists 112–113 D-Index: 72 scientists 114–115 D-Index: 73 scientists 116–117 D-Index: 64 scientists 118–119 D-Index: 53 scientists 120–121 D-Index: 60 scientists 122–123 D-Index: 54 scientists 124–125 D-Index: 43 scientists 126–127 D-Index: 38 scientists 128–129 D-Index: 49 scientists 130–131 D-Index: 26 scientists 132–133 D-Index: 18 scientists 134–135 D-Index: 23 scientists 136–137 D-Index: 32 scientists 138–139 D-Index: 32 scientists 140–141 D-Index: 27 scientists 142–143 D-Index: 19 scientists 144–145 D-Index: 22 scientists 146–147 D-Index: 12 scientists 148–149 D-Index: 16 scientists 150–151 D-Index: 14 scientists 152–153 D-Index: 10 scientists 154–155 D-Index: 13 scientists 156–157 D-Index: 10 scientists 158–159 D-Index: 7 scientists 160–161 D-Index: 9 scientists 162–163 D-Index: 13 scientists 164–165 D-Index: 4 scientists 166 D-Index: 4 scientists 167+ D-Index: 98 scientists
40 D-Index 167+

This scientist: 123 D-Index — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 167 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Biology and Biochemistry in United Kingdom Leader Award
  • 2025 - Research.com Biology and Biochemistry in United Kingdom Leader Award
  • 2023 - Research.com Biology and Biochemistry in United Kingdom Leader Award
  • 2016 - Fellow of the Royal Society, United Kingdom

Overview

Paul Workman is affiliated with the Institute of Cancer Research in the United Kingdom. Their research primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. They have contributed extensively to Molecular Biology, Computational Theory and Mathematics, Oncology, Cell Biology, and Economics and Econometrics.

The scientist's work covers a range of topics including:

  • Heat shock proteins research
  • Computational Drug Discovery Methods
  • Endoplasmic Reticulum Stress and Disease
  • Protein Degradation and Inhibitors
  • Click Chemistry and Applications
  • Protein Structure and Dynamics
  • Ubiquitin and proteasome pathways

Among recent publications, they co-authored:

  • "The kinase polypharmacology landscape of clinical PARP inhibitors," 2020, Scientific Reports
  • "canSAR: update to the cancer translational research and drug discovery knowledgebase," 2020, Nucleic Acids Research
  • "Expanding Chemical Probe Space: Quality Criteria for Covalent and Degrader Probes," 2023, Journal of Medicinal Chemistry
  • "Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer," 2020, PLoS ONE
  • "Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma," 2020, Journal of Clinical Investigation

They have frequently published in venues including:

  • Cancer Research
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Nucleic Acids Research
  • Nature Communications
  • Clinical Cancer Research

Paul Workman has collaborated regularly with other researchers, notably:

  • Paul A. Clarke
  • Bissan Al-Lazikani
  • Robert te Poele
  • Albert A. Antolín
  • Marissa Powers

In recognition of their contributions, they were awarded the title of Fellow of the Royal Society, United Kingdom, in 2016.

Best Publications

  • Guidelines for the welfare and use of animals in cancer research

    P Workman;E O Aboagye;F Balkwill;A Balmain

  • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers

    Georgios Vlachogiannis;Somaieh Hedayat;Alexandra Vatsiou;Yann Jamin

  • Combinatorial drug therapy for cancer in the post-genomic era

    Bissan Al-Lazikani;Udai Banerji;Udai Banerji;Paul Workman

  • The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer†

    Adrian J. Folkes;Khatereh Ahmadi;Wendy K. Alderton;Sonia Alix

  • Hsp90 molecular chaperone inhibitors: are we there yet?

    Len Neckers;Paul Workman

  • Imaging biomarker roadmap for cancer studies.

    James P.B. O'Connor;Eric O. Aboagye;Judith E. Adams;Hugo J.W.L. Aerts;Hugo J.W.L. Aerts

  • The promise and peril of chemical probes.

    Cheryl H. Arrowsmith;James E. Audia;Christopher Austin;Jonathan Baell

  • Challenges to curing primary brain tumours

    Kenneth Aldape;Kevin M Brindle;Louis Chesler;Rajesh Chopra

  • HSP90 as a new therapeutic target for cancer therapy: the story unfolds.

    Alison Maloney;Paul Workman

  • Discovery of small molecule cancer drugs: Successes, challenges and opportunities

    Swen Hoelder;Paul A. Clarke;Paul Workman

  • Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.

    Timothy A Yap;Michelle D Garrett;Mike I Walton;Florence Raynaud

  • Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.

    Paul Workman;Francis Burrows;Len Neckers;Neal Rosen

  • Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1.

    Barry Panaretou;Giuliano Siligardi;Philippe Meyer;Alison Maloney

  • The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations

    Martin O Leach;K Brindle;J Evelhoch;John R Griffiths

  • Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies

    Udai Banerji;Anne O'Donnell;Michelle Scurr;Simon Pacey

  • NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis

    Suzanne A Eccles;Andy Massey;Florence I Raynaud;Swee Y Sharp

  • The Hsp90 molecular chaperone: an open and shut case for treatment

    Laurence H. Pearl;Chrisostomos Prodromou;Paul Workman

  • 4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer

    Paul A. Brough;Wynne Aherne;Xavier Barril;Jenifer Borgognoni

  • New approaches to molecular cancer therapeutics.

    Ian Collins;Paul Workman

  • Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

    Florence I. Raynaud;Suzanne Eccles;Paul A. Clarke;Angela Hayes

Frequent Co-Authors

Florence I. Raynaud
Florence I. Raynaud Institute of Cancer Research
Suzanne A. Eccles
Suzanne A. Eccles Institute of Cancer Research
Martin O. Leach
Martin O. Leach Royal Marsden NHS Foundation Trust
Ian Collins
Ian Collins PharmEnable Therapeutics
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Ian Judson
Ian Judson Institute of Cancer Research
Laurence H. Pearl
Laurence H. Pearl University of Sussex
Chrisostomos Prodromou
Chrisostomos Prodromou University of Sussex
Stan B. Kaye
Stan B. Kaye Royal Marsden NHS Foundation Trust
Andrew D.J. Pearson
Andrew D.J. Pearson Royal Marsden NHS Foundation Trust

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in expanding your studies beyond Biology and Biochemistry, there are several online degree options that align with health and science careers. Many reputable institutions now offer flexible online programs designed for busy students and professionals, making it easier to advance your education wherever you are.

Healthcare leadership roles are in high demand, and doctoral programs for healthcare administration can provide advanced skills to manage hospitals or health systems. For those interested in medication and patient care, enrolling in an online pharmacy school can open doors to pharmaceutical careers.

Movement science is another growing field. You can earn your degree through an exercise science degree online accredited program, which focuses on fitness, rehabilitation, and sports performance. Alternatively, a kinesiology online degree allows you to explore how physical activity impacts health and disease.

With these online pathways, you can build expertise that supports a range of meaningful, in-demand healthcare and life science careers, all while balancing your studies with other commitments.

Best Scientists Citing Paul Workman

Trending Scientists

Recently Published Articles